全球标靶治疗市场规模、份额、成长分析，按类型（单株抗体和小分子）、按应用（乳腺癌、结直肠癌）- 2024-2031 年行业预测

Global Targeted Therapeutics Market Size, Share, Growth Analysis, By Type(Monoclonal Antibodies and Small Molecule), By Application(Breast Cancer, Colorectal Cancer) - Industry Forecast 2024-2031

出版日期: 2024年03月09日 | 出版商:

SkyQuest | 英文 219 Pages | 商品交期: 3-5个工作天内

价格

简介目录

2022年全球标靶治疗市场规模为705.7亿美元，预计将从2023年的720.5亿美元成长到2031年的850.8亿美元，预测期间（2024-2031年）CAGR为2.10%。

由于生物製剂的日益普及和扩张，市场经历了快速成长。此外，由于生物技术领域投资增加，全球市场正在扩张。由于生物製品行业的显着增长和进步，单株抗体已成为最受欢迎的治疗方法之一。这些标靶治疗在有效阻止肿瘤细胞增生方面发挥关键作用。未来几年，线上药局的激增预计将推动特定治疗药物的销售。影响该行业成长的另一个重要因素是政府在全球目标治疗市场开发先进医疗基础设施方面的支出不断增加。到 2040 年，全球预计将出现 2,840 万例。此外，人们对标靶治疗药物可用性的认识不断提高正在推动全球市场的扩张。然而，市场成长预计将受到标靶治疗和药物相关副作用的阻碍。

市场概况
北美洲
- 美国
- 加拿大
欧洲
- 德国
- 西班牙
- 法国
- 英国
- 欧洲其他地区
亚太地区
- 中国
- 印度
- 日本
- 韩国
- 亚太其他地区
拉丁美洲
- 巴西
- 拉丁美洲其他地区
中东和非洲 (MEA)
- 海湾合作委员会国家
- 南非
- MEA 的其余部分

竞争格局

前 5 名玩家比较
2021 年关键参与者的市场定位
主要市场参与者所采取的策略
最佳制胜策略
近期市集活动
主要公司市占率（%），2021年

主要公司简介

Roche Holding AG
Novartis AG
Amgen Inc.
AstraZeneca Plc
Merck & Co. Inc.
Pfizer Inc.
Eli Lilly and Company
Bayer AG
Bristol-Myers Squibb Company
GlaxoSmithKline Plc
AbbVie Inc.
Biogen Inc.
Sanofi SA
Johnson & Johnson
Takeda Pharmaceutical Co. Ltd.
Gilead Sciences Inc.
Vertex Pharmaceuticals Inc.
Teva Pharmaceutical Industries Ltd.
Celgene Corporation (a subsidiary of Bristol-Myers Squibb Company)
Regeneron Pharmaceuticals Inc.

简介目录

Product Code: SQMIG35H2052

Global Targeted Therapeutics Market size was valued at USD 70.57 billion in 2022 and is poised to grow from USD 72.05 billion in 2023 to USD 85.08 billion by 2031, growing at a CAGR of 2.10% during the forecast period (2024-2031).

The market has experienced rapid growth attributed to the increasing popularity and expansion of biologics. Furthermore, the global market is witnessing expansion due to heightened investments in the biotechnology sector. Monoclonal antibodies have emerged as one of the most sought-after treatments resulting from the remarkable growth and advancement in the biologics industry. These targeted therapeutics play a pivotal role in halting the proliferation of tumor cells effectively. Over the forthcoming years, the proliferation of online pharmacies is expected to drive sales of specific therapeutic drugs. Another significant factor poised to influence the industry's growth is the escalating government expenditure on developing advanced healthcare infrastructure across the global targeted therapeutics market. By 2040, an estimated 28.4 million cases are projected worldwide. Moreover, increasing awareness among the population regarding the availability of targeted therapeutics is propelling the expansion of the global market. However, the market growth is expected to be hindered by the side effects associated with targeted therapies and drugs.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Targeted Therapeutics Market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Targeted Therapeutics Market Segmental Analysis

Global targeted therapeutics market is segmented based on type, application, and region. By type, the market is segmented into Monoclonal antibodies and small molecule. By application, the market is segmented into Breast cancer, colorectal cancer, lung cancer, and renal cancer. By region the market is segmented into North America, Europe, Asia Pacific, Latin America, and MEA.

Drivers of the Global Targeted Therapeutics Market

The widespread prevalence of cancer serves as the main catalyst for the growth of the targeted therapeutics market. The rising number of smokers contributes significantly to this trend, as smoking is identified as the leading cause of cancer-related deaths globally. In 2021, an estimated 235,760 individuals in the United States alone are expected to receive a lung cancer diagnosis, with approximately 130,000 deaths attributed to lung cancer annually in the country. Moreover, the global increase in smoking prevalence, which has surged by over 19%, underscores that this issue extends beyond the borders of the United States.

Restraints in the Global Targeted Therapeutics Market

Targeted therapies and their corresponding medications play a crucial role in cancer treatment across various applications. Nevertheless, significant health concerns accompany such treatments, posing a potential obstacle to market growth. Common risks associated with targeted therapy include hepatitis, diarrhea, and liver issues like elevated liver enzymes. Additionally, individuals undergoing targeted therapy may experience adverse effects such as hair loss, skin rashes, reduced sperm production, and hypertension.

Market Trends of the Global Targeted Therapeutics Market

Key players in the global therapeutics market are actively engaged in collaboration agreements, acquisitions, and new product launches, all of which are anticipated to drive market growth. Several competitors in this market have implemented expansion strategies to enhance their market presence. For instance, PubMed Inc. has introduced upgraded versions of complement-targeted therapies designed to address various disease and pathological conditions, thereby boosting the sales of complement-targeted therapies.

Executive Summary

Market Overview
Wheel of Fortune

Research Methodology

Information Procurement
Secondary & Primary Data Sources
Market Size Estimation
Market Assumptions & Limitations

Parent Market Analysis

Market Overview
Market Size
Market Dynamics
- Drivers
- Opportunities
- Restraints
- Challenges

Key Market Insights

Technology Analysis
Pricing Analysis
Supply Chain Analysis
Value Chain Analysis
Ecosystem of the Market
IP Analysis
Trade Analysis
Startup Analysis
Raw Material Analysis
Innovation Matrix
Pipeline Product Analysis
Macroeconomic Indicators
Top Investment Analysis
Key Success Factor
Degree of Competition

Market Dynamics & Outlook

Market Dynamics
- Drivers
- Opportunities
- Restraints
- Challenges
Regulatory Landscape
Porters Analysis
- Competitive rivalry
- Threat of Substitute Products
- Bargaining Power of Buyers
- Threat of New Entrants
- Bargaining Power of Suppliers
Skyquest Special Insights on Future Disruptions
- Political Impact
- Economic Impact
- Social Impact
- Technical Impact
- Environmental Impact
- Legal Impact

Global Targeted Therapeutics Market by Type

Market Overview
Monoclonal Antibodies and Small Molecule

Global Targeted Therapeutics Market by Application

Market Overview
Breast Cancer
Colorectal Cancer
Lung Cancer
Renal Cancer

Global Targeted Therapeutics Market Size by Region

Market Overview
North America
- USA
- Canada
Europe
- Germany
- Spain
- France
- UK
- Rest of Europe
Asia Pacific
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
Latin America
- Brazil
- Rest of Latin America
Middle East & Africa (MEA)
- GCC Countries
- South Africa
- Rest of MEA

Competitive Landscape

Top 5 Player Comparison
Market Positioning of Key Players, 2021
Strategies Adopted by Key Market Players
Top Winning Strategies
- By Development
- By Company
- By Year
Recent Activities in the Market
Key Companies Market Share (%), 2021

Key Company Profiles

Roche Holding AG
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Novartis AG
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Amgen Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
AstraZeneca Plc
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Merck & Co. Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Pfizer Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Eli Lilly and Company
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Bayer AG
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Bristol-Myers Squibb Company
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
GlaxoSmithKline Plc
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
AbbVie Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Biogen Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Sanofi S.A.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Johnson & Johnson
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Takeda Pharmaceutical Co. Ltd.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Gilead Sciences Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Vertex Pharmaceuticals Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Teva Pharmaceutical Industries Ltd.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Celgene Corporation (a subsidiary of Bristol-Myers Squibb Company)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Regeneron Pharmaceuticals Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments